Guggenheim Maintains Buy on Vaxcyte, Raises Price Target to $125

Benzinga · 1d ago
Guggenheim analyst Seamus Fernandez maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price target from $116 to $125.